| ★ |  Structuring Obesity Trials to Optimize Patient Retention and Data Integrity | | 18 | Estados Unidos | |
| 19 |  GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals | Metabolic Mind @metabolicmind | 49.3K | Estados Unidos | 87 |
| 12 |  Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS | | 4.3K | Estados Unidos | 87 |
| 15 |  Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight | | 1.1K | Estados Unidos | 87 |
| 13 |  Inside the VESPER-3 Results: Berobenatide's Weight Loss Potential | | 839 | Estados Unidos | 87 |
| 14 |  Diabetes Dialogue: The ADA’s Statement on Diabetes Tech Integration, With Eugene Wright Jr., MD | | 584 | Estados Unidos | 87 |
| 11 |  Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss | | 533 | Estados Unidos | 87 |
| 9 |  TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity | | 350 | Estados Unidos | 88 |
| 6 |  Berobenatide Monthly GLP-1 Injectable Shows Promise for Weight Loss | | 250 | Estados Unidos | 88 |
| 16 |  Diabetes Dialogue: Tech, Screening, and Care Highlights from ADCES 2026 | | 224 | Estados Unidos | 87 |
| 10 |  Diabetes Dialogue: CKM Systems, Triple Agonists, and a Sensor Scandal Ahead of ADA | | 179 | Estados Unidos | 87 |
| 2 |  Rapid Evolution in GLP-1s and Therapeutics at ADA 2026 | | 171 | Estados Unidos | 89 |
| 18 |  Diabetes Dialogue: Tegoprubart and Freedom from Insulin in Type 1 Diabetes | | 143 | Estados Unidos | 87 |
| 5 |  Diabetes Dialogue: CONNECT, TRANSCEND, and TRIUMPH at ADA 2026 | | 114 | Estados Unidos | 88 |
| 4 |  Improving GLP-1 Adherence in Patients With Diabetes, With Vivian Fonseca, MD | | 91 | Estados Unidos | 88 |
| 8 |  Diabetes Dialogue: The International Diabetes Federation and Care in India, With Amit Gupta, MBBS | | 79 | Estados Unidos | 88 |
| 1 |  Incretins, Monitors, and Insulin Titration at ADA 2026 | | 76 | Estados Unidos | 89 |
| 7 |  Diabetes Dialogue: Signos and the Science of Weight Loss | | 75 | Estados Unidos | 88 |
| 20 |  GLP-1 Discontinuation in Type 2 Diabetes: What Happens When Patients Stop? | | 64 | Estados Unidos | 87 |
| 3 |  Implications of the Phase 4 Trial of Metreleptin in Patients With General Lipodystrophy | | 55 | Estados Unidos | 88 |
| 17 |  Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients | | 53 | Estados Unidos | 87 |